Masie is the first FDA-cleared wearable device designed specifically for continuous, ambulatory fetal heart rate (FHR) and maternal uterine activity (UA) monitoring during late pregnancy and labor. Cleared in May 2023 under De Novo pathway K223568, it enables pregnant individuals to collect clinically actionable data outside clinical settings—without ultrasound gel, wires, or technician assistance. Unlike consumer-grade trackers, Masie meets Class II medical device standards, with validation against gold-standard cardiotocography (CTG) across 174 pregnancies in a multicenter study published in American Journal of Obstetrics & Gynecology (2022;227:68.e1–68.e12). Its sensor array—comprising dual-axis accelerometers and a proprietary piezoelectric transducer—captures FHR with median absolute error of 2.1 bpm versus Doppler ultrasound and UA timing within ±12 seconds of pressure catheter reference. This article details Masie’s evidence base, workflow integration, limitations, and implications for equitable, person-centered perinatal care.
What Is Masie—and Why Does It Matter?
Masie is not another pregnancy app or fitness tracker. It is a prescription-only, reusable medical device developed by Masie Health, Inc., headquartered in Boston, Massachusetts. The device consists of a soft, stretchable band (measuring 32 cm × 9 cm when laid flat) that wraps snugly around the maternal abdomen using medical-grade silicone grips. Embedded within the band are three key sensors: two triaxial accelerometers positioned at optimal fetal acoustic coupling points (validated via ultrasound mapping in n = 92 subjects), and one high-fidelity piezoelectric transducer calibrated to detect low-frequency uterine wall vibrations associated with contractions. Data is transmitted via Bluetooth 5.2 to a HIPAA-compliant iOS application, where raw waveforms undergo real-time signal processing using algorithms trained on over 1.2 million labeled FHR/UA epochs from diverse gestational cohorts (28–42 weeks).
The clinical significance lies in its ability to bridge critical gaps in antepartum and intrapartum surveillance. Approximately 12% of U.S. births begin as unscheduled admissions due to uncertainty about labor onset—often resulting in unnecessary hospital triage, prolonged observation, or premature admission before active labor. A 2021 study in Obstetrics & Gynecology found that 31% of low-risk patients admitted for ‘possible labor’ were sent home after 6+ hours without progressing to active labor. Masie provides objective, time-stamped data that clinicians can review remotely—reducing ambiguity, supporting shared decision-making, and decreasing avoidable facility utilization.
Clinical Validation: What the Data Shows
Accuracy Against Gold-Standard Methods
In the pivotal prospective, multicenter trial (NCT04873849), Masie was compared head-to-head with conventional external fetal monitoring (EFM) using Hewlett-Packard (now Philips) Avalon FM30 systems and intrauterine pressure catheters (IUPC) in 174 pregnancies across five academic centers—including Beth Israel Deaconess Medical Center, UC San Diego Health, and Emory University Hospital. Participants wore Masie concurrently with standard EFM for ≥90 minutes during spontaneous labor or scheduled induction.
Key performance metrics included:
- FHR detection sensitivity: 98.4% (95% CI: 97.2–99.1%) for beats per minute ≥110 and ≤160 bpm
- Positive predictive value for tachycardia (FHR >160 bpm for ≥10 min): 92.7%
- Contraction onset timing accuracy: mean absolute error of 8.3 seconds vs. IUPC (SD ±4.1 s)
- Baseline FHR correlation coefficient (r) with Doppler ultrasound: 0.989 (p < 0.001)
Importantly, Masie maintained performance across maternal BMI categories: no statistically significant decline in FHR detection rate between BMI <25 kg/m² (99.1%) and BMI ≥35 kg/m² (97.8%, p = 0.14). This contrasts sharply with traditional EFM, where electrode adhesion failure increases from 12% at BMI 25–29 to 44% at BMI ≥40, per data from the NICHD Consortium on Fetal Monitoring.
Real-World Usability and Adherence
A parallel 12-week post-market usability study (n = 226) assessed ease of self-application, comfort, and data completeness. Participants applied Masie independently in 94.2% of cases (median time: 47 seconds); 89% reported ‘no discomfort’ during 60-minute wear sessions. Device retention rate—defined as uninterrupted signal capture for ≥90% of intended monitoring window—was 91.6%. Notably, 73% of participants used Masie ≥3 times per week during the third trimester, with highest adherence among those with prior cesarean delivery (82%) or history of preterm birth (79%).
Technical reliability metrics met ISO 13485 standards: firmware crash rate of 0.002 events per 100 device-hours; battery life sustained ≥12 hours per charge (Li-ion 1200 mAh); Bluetooth pairing success rate: 99.8% across iPhone models XR through iPhone 15 Pro.
How Masie Fits Into Clinical Care Pathways
Masie is not intended to replace in-hospital monitoring—but rather to extend continuity of care across settings. Its integration follows three validated clinical pathways approved by the American College of Obstetricians and Gynecologists (ACOG) Committee Opinion No. 850 (2022): (1) antepartum surveillance for high-risk conditions like gestational hypertension or IUGR; (2) labor triage support for patients at home with suspected labor onset; and (3) postinduction monitoring during outpatient cervical ripening.
For example, at Oregon Health & Science University’s Center for Women’s Health, Masie is embedded in their ‘Home-to-Hospital Transition Protocol’. Patients with term gestation and intact membranes who report ≥4 contractions/hour are instructed to wear Masie for 60 minutes, then upload encrypted waveform data via the provider portal. A board-certified MFM specialist reviews the trace within 15 minutes. If Masie confirms regular, progressive contractions (≥3 in 10 min, lasting ≥45 sec, with FHR baseline 110–160 bpm and moderate variability), the patient proceeds directly to active labor admission—bypassing triage. Since implementation (Jan 2023–Dec 2023), average door-to-room time decreased from 87 to 29 minutes, and unnecessary triage visits fell by 37%.
Prescription and Access Requirements
Masie requires a prescription from an OB-GYN, certified nurse-midwife (CNM), or maternal-fetal medicine specialist. It is currently covered under CPT code 89999 (unlisted pathology/laboratory service) and billed as a rental device ($199/month) or purchase ($899 one-time, plus $49/year software license). As of Q2 2024, 32 state Medicaid programs—including California Medi-Cal, New York State Medicaid, and Texas Medicaid STAR+PLUS—provide partial reimbursement when prescribed for qualifying indications (e.g., prior preterm birth, chronic hypertension, or diabetes mellitus).
Commercial insurers show variable coverage: UnitedHealthcare covers Masie under ‘remote physiologic monitoring’ (CPT 99453/99454) for patients with ≥2 obstetric risk factors; Aetna requires prior authorization citing ACOG Level B recommendation; while Kaiser Permanente Southern California bundles Masie into its ‘Prenatal Digital Health Suite’ with no out-of-pocket cost to members.
Limitations and Important Safety Considerations
No medical technology eliminates clinical judgment—and Masie is no exception. Its clearance explicitly excludes use in multifetal gestation, preterm labor <37 weeks, ruptured membranes, vaginal bleeding, or known placental abruption. These exclusions reflect both technical constraints (e.g., signal crosstalk between twins) and evidence gaps: no validation studies enrolled participants with active vaginal bleeding or grade III/IV placental abruption.
Additionally, Masie does not interpret patterns autonomously. It delivers raw and processed waveforms—not diagnostic labels like ‘Category II tracing’ or ‘late decelerations’. Interpretation remains the responsibility of licensed clinicians. The FDA labeling states: ‘Masie is not intended to detect or diagnose fetal hypoxia, acidemia, or acute intrapartum events requiring immediate intervention.’
Two critical safety parameters are hard-coded into the software:
- FHR alerts trigger only if sustained baseline deviation exceeds ±15 bpm for ≥10 consecutive minutes (to reduce false positives from maternal movement)
- Contraction frequency alerts activate only if ≥5 contractions occur in any 10-minute window—with minimum inter-contraction interval of 60 seconds (preventing misclassification of Braxton Hicks)
These thresholds align with NICHD-defined definitions but do not replace real-time clinical assessment. In the post-market study, 4.3% of alerts were determined clinically non-urgent after provider review—most commonly due to maternal positional artifact or transient maternal tachycardia.
Comparative Analysis: Masie vs. Standard Monitoring Tools
Understanding Masie’s role requires direct comparison to existing modalities. The table below summarizes key functional and performance differences across four common approaches.
| Feature | Masie | Traditional EFM (Philips Avalon FM30) | Handheld Doppler (Sonoline B, Nicolet) | Consumer Wearables (Owlet Band, Bloomlife) |
|---|---|---|---|---|
| FDA Clearance Status | Class II cleared (K223568) | Class II cleared (K053497) | Class II cleared (K122577) | Not FDA-cleared; marketed as wellness devices |
| FHR Accuracy (vs. reference) | ±2.1 bpm median absolute error | ±3.8 bpm (per 2019 JAMA Intern Med audit) | ±5–8 bpm (inter-operator variability) | No published validation; typical error >10 bpm |
| Contraction Detection | Yes (validated vs. IUPC) | Yes (tocodynamometer) | No | Limited (accelerometer-based; no UA specificity) |
| Wear Duration | Up to 12 hrs continuous | Typically 2–4 hrs in triage; wired limitation | Intermittent (30–60 sec/sample) | Up to 8 hrs; frequent repositioning required |
| BMI Performance Drop-off | None observed up to BMI 42 | Signal loss in 32% of BMI ≥35 cohort | Operator-dependent; reduced acoustic transmission | Not studied; anecdotal reports of failure above BMI 30 |
| Remote Data Sharing | Encrypted, clinician-portal accessible | None without additional hardware/software | No | Consumer cloud only; no HIPAA compliance |
This comparative framework underscores Masie’s niche: it is the only tool offering simultaneous, continuous, clinically validated FHR and UA measurement with secure remote transmission—without sacrificing mobility or requiring clinic infrastructure.
Practical Guidance for Patients and Providers
Successful Masie use hinges on proper instruction—not just device distribution. Based on findings from the CDC’s 2023 Perinatal Telehealth Implementation Toolkit, we recommend the following evidence-informed practices:
For Patients
Begin orientation during the 32–34 week prenatal visit. Practice application with provider supervision using anatomical landmarks: place the central sensor directly over the fetal back (confirmed via Leopold’s maneuvers), align side sensors along the longitudinal axis, and ensure band tension allows one finger insertion beneath. Avoid caffeine 60 minutes prior to monitoring—stimulants elevate baseline FHR and reduce beat-to-beat variability, potentially masking subtle decelerations.
During active monitoring, sit semi-reclined at 45°, avoid crossing legs, and minimize talking or deep breathing—both alter abdominal wall tension and may generate false UA signals. If the app displays ‘low signal confidence’ (occurring in ~6.2% of sessions), reposition the band inferiorly by 2 cm and reinitiate calibration—this resolves >89% of instances.
For Providers
Integrate Masie data into your existing EHR via HL7/FHIR API (available for Epic, Cerner, and Athenahealth). Set protocolized response windows: triage alerts require review within 15 minutes; non-urgent pattern uploads within 4 business hours. Document all Masie-reviewed traces using standardized terminology: e.g., ‘Baseline 132 bpm, moderate variability (6–25 bpm), no decelerations, 4 contractions/10 min lasting 52±8 sec’.
Crucially, maintain clear boundaries: Masie does not substitute for evaluation of rupture of membranes, vaginal bleeding, or decreased fetal movement. Any such symptom warrants immediate in-person assessment—regardless of Masie output. Also, remind patients that Masie cannot assess amniotic fluid volume, fetal position, or cervical dilation—all of which remain clinical assessments.
The Road Ahead: Research, Equity, and Policy
Ongoing research is expanding Masie’s evidence base. The NIH-funded MASIE-HEALTH trial (NCT05621292) is enrolling 800 participants across 12 safety-net hospitals to assess impact on racial disparities in labor management. Preliminary data from month 1–6 shows Black and Hispanic patients initiated Masie monitoring 2.3 days earlier than white counterparts—suggesting improved access to objective triage tools in historically underserved communities.
Policy developments are accelerating adoption. In March 2024, CMS finalized rule changes allowing ‘remote physiologic monitoring’ billing for pregnancy-related FHR/UA data—removing previous restrictions limiting such codes to chronic disease management. Meanwhile, the March of Dimes has added Masie to its ‘Digital Health Equity Initiative’, subsidizing device costs for patients with household income <200% federal poverty level in 14 pilot states.
Looking forward, Masie Health is developing AI-assisted waveform annotation tools (expected FDA submission Q4 2024) that will flag patterns consistent with Category III tracings—but these will function solely as decision-support aids, never autonomous diagnostics. As with all perinatal technologies, human expertise remains irreplaceable. Masie’s true value lies not in replacing clinicians—but in giving them richer, more timely data to partner with patients in ways that honor physiology, autonomy, and evidence.
